Trial Profile
Study to evaluate the safety and efficacy of PAZ320 when added to oral agents or insulin in patients with type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs BTI 320 (Primary) ; Antihyperglycaemics; Insulin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Boston Therapeutics
- 22 Sep 2014 Results published in a Boston Therapeutics media release.
- 04 Sep 2013 Results have been published in the July/August issue of Endocrine Practice according to a Boston Therapeutics media release. Results were also summarised in the media release.
- 26 Feb 2013 Results have been published electronically in an abstract ahead of print in Endocrine Practice according to a Boston Therapeutics media release. The full article is expected to be published in the July/August issue of the journal.